GLIPR2

Across TCGA pan-cancer cohorts, GLIPR2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLIPR2 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GLIPR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLIPR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where GLIPR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.885	1.000	.019	18	view →
LUAD	OS	Quartile	III,IV	0.385	0.995	.001	18	view →
PDAC	DFS	Quartile	III,IV	0.439	1.000	.022	12	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	9	view →
LSCC	DFS	Quartile	II,III,IV	0.543	1.000	.005	8	view →
UCEC	DFS	Tertile	All	0.904	1.000	.022	8	view →
HNSC	DFS	Median	IV	0.875	0.674	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLIPR2–COAD (DFS)

Open the COAD breakdown →